Presepsin (sCD14-ST): could it be a novel marker for the diagnosis of ST elevation myocardial infarction?

Abstract

IntroductionAcute myocardial infarction (AMI) could be considered to be a state of inflammation. Many inflammatory markers have been evaluated in the AMI setting so far. Presepsin (PSP) is a novel biomarker for diagnosis and prognosis of systemic inflammation that has not been studied in the AMI setting to date. In this study, we aimed to examine serum PSP levels in patients with acute ST elevation myocardial infarction (STEMI).Material and methodsForty-eight patients with STEMI and fifty healthy controls without coronary artery disease, verified by coronary angiography, were included in the study. Together with routine laboratory tests needed for STEMI, plasma concentrations of PSP were measured in peripheral venous blood samples of the participants.ResultsPlasma PSP and troponin levels were significantly higher in patients with STEMI than controls (1988.89 ±3101.55 vs. 914.22 ±911.35 pg/ml, p = 0.001 and 3.46 ±3.39 vs. 0.08 ±0.43 ng/ml, p = 0.001, respectively). The cut-off value for PSP of 447 pg/ml was found to detect STEMI with 87.5% sensitivity, 44% specificity, 60% positive predictive value and 78.5% negative predictive value.ConclusionsIn this study, PSP levels were found to be significantly elevated in patients with STEMI together with high-sensitivity troponins. The PSP may be a new marker for AMI detection. Large scale studies are needed to reveal the importance of PSP in the diagnosis and prognosis of AMI.

Serum Presepsin Levels in Patients with Decompensated Heart Failure

“…In this study, we used the methods of our previous study. (9) Fifty patients admitted to coronary care unit with acute decompensated HF and 51 age-matched control group patients without HF as verified by echocardiography were enrolled in this study. The study protocol was approved by the local ethics committee review board.…”

“…Patients with diabetes mellitus and hypertension were not excluded from the study. (9) The glomerular filtration rate was estimated by using the Modification of Diet in Renal Disease (MDRD) equation at admission. Body mass index (BMI) was calculated due to World Health Organization criteria.…”

“…(11) Patients with known inflammatory disease, serious valvular disease, uncontrolled hypertension, serious hepatic failure, fever, acute or chronic infection, receiving antibiotic therapy, muscle aches, immunoproliferative disease, osteoporosis, rheumatic disease, cancer, younger than 18 years old and older than 70 years old, estimated glomerular filtration rate (eGFR) < 60 mL / min / 1.73 m2 were excluded. (9) Laboratory measurements Blood samples for PSP and other biochemical measurements were taken from the patients once the diagnosis of decompensated HF was made and volunteers in the control group. All of the laboratory measurements of the study participants consisting of white blood cell count (WBC), high sensitive CRP (hsCRP) and creatinine were performed.…”

“…Blood samples for PSP measurement were obtained by vein puncture into ethylene diamine tetra acetic acid (EDTA) blood collection tubes without additives and immediately centrifuged at 2500 rpm for 10 minutes. (9) The serum was collected and stored at -80 ºC until analysis up to six months. The samples were thawed out once.…”

“…All the assays were performed according to the manufacturer's recommendations with the Pathfast® immunoassay analytical system (Progen Biotechnik GmbH, Germany and Mitsubishi Chemical Medience Corporation, Japan) using plasma from EDTA tubes. (9) Heparinized whole blood samples were centrifuged at 1000 rpm for 5 minutes and NT-ProBNP measurements were performed using chemiluminescence method (Cobas e411, Roche Diagnostics, Basel, Switzerland). (9) Following centrifugation at 1000 rpm for 10 minutes of plain tubes, creatinine and hsCRP levels were measured according to the manufacturer's recommendations with using related methods (Cobas c501, Roche Diagnostics, Basel, Switzerland).…”